193 related articles for article (PubMed ID: 27491285)
21. Disruption of the p70(s6k)/p85(s6k) gene reveals a small mouse phenotype and a new functional S6 kinase.
Shima H; Pende M; Chen Y; Fumagalli S; Thomas G; Kozma SC
EMBO J; 1998 Nov; 17(22):6649-59. PubMed ID: 9822608
[TBL] [Abstract][Full Text] [Related]
22. Regulation and localization of ribosomal protein S6 kinase 1 isoforms.
Kim D; Akcakanat A; Singh G; Sharma C; Meric-Bernstam F
Growth Factors; 2009 Feb; 27(1):12-21. PubMed ID: 19085255
[TBL] [Abstract][Full Text] [Related]
23. Modulation of hypothalamic S6K1 and S6K2 alters feeding behavior and systemic glucose metabolism.
Tavares MR; Lemes SF; de Fante T; Saenz de Miera C; Pavan ICB; Bezerra RMN; Prada PO; Torsoni MA; Elias CF; Simabuco FM
J Endocrinol; 2020 Jan; 244(1):71-82. PubMed ID: 31557728
[TBL] [Abstract][Full Text] [Related]
24. PIAS1 is a crucial factor for prostate cancer cell survival and a valid target in docetaxel resistant cells.
Puhr M; Hoefer J; Neuwirt H; Eder IE; Kern J; Schäfer G; Geley S; Heidegger I; Klocker H; Culig Z
Oncotarget; 2014 Dec; 5(23):12043-56. PubMed ID: 25474038
[TBL] [Abstract][Full Text] [Related]
25. LY303511 (2-piperazinyl-8-phenyl-4H-1-benzopyran-4-one) acts via phosphatidylinositol 3-kinase-independent pathways to inhibit cell proliferation via mammalian target of rapamycin (mTOR)- and non-mTOR-dependent mechanisms.
Kristof AS; Pacheco-Rodriguez G; Schremmer B; Moss J
J Pharmacol Exp Ther; 2005 Sep; 314(3):1134-43. PubMed ID: 15923340
[TBL] [Abstract][Full Text] [Related]
26. Osteopontin splice variants expression is involved on docetaxel resistance in PC3 prostate cancer cells.
Nakamura KD; Tilli TM; Wanderley JL; Palumbo A; Mattos RM; Ferreira AC; Klumb CE; Nasciutti LE; Gimba ER
Tumour Biol; 2016 Feb; 37(2):2655-63. PubMed ID: 26404131
[TBL] [Abstract][Full Text] [Related]
27. The ubiquitination of ribosomal S6 kinases is independent from the mitogen-induced phosphorylation/activation of the kinase.
Gwalter J; Wang ML; Gout I
Int J Biochem Cell Biol; 2009 Apr; 41(4):828-33. PubMed ID: 18786649
[TBL] [Abstract][Full Text] [Related]
28. ABCC4 Decreases docetaxel and not cabazitaxel efficacy in prostate cancer cells in vitro.
Oprea-Lager DE; Bijnsdorp IV; VAN Moorselaar RJ; VAN DEN Eertwegh AJ; Hoekstra OS; Geldof AA
Anticancer Res; 2013 Feb; 33(2):387-91. PubMed ID: 23393328
[TBL] [Abstract][Full Text] [Related]
29. Revealing Different Roles of the mTOR-Targets S6K1 and S6K2 in Breast Cancer by Expression Profiling and Structural Analysis.
Karlsson E; Magić I; Bostner J; Dyrager C; Lysholm F; Hallbeck AL; Stål O; Lundström P
PLoS One; 2015; 10(12):e0145013. PubMed ID: 26698305
[TBL] [Abstract][Full Text] [Related]
30. Over-expression of lipocalin 2 promotes cell migration and invasion through activating ERK signaling to increase SLUG expression in prostate cancer.
Ding G; Fang J; Tong S; Qu L; Jiang H; Ding Q; Liu J
Prostate; 2015 Jun; 75(9):957-68. PubMed ID: 25728945
[TBL] [Abstract][Full Text] [Related]
31. Deletion of ribosomal S6 kinases does not attenuate pathological, physiological, or insulin-like growth factor 1 receptor-phosphoinositide 3-kinase-induced cardiac hypertrophy.
McMullen JR; Shioi T; Zhang L; Tarnavski O; Sherwood MC; Dorfman AL; Longnus S; Pende M; Martin KA; Blenis J; Thomas G; Izumo S
Mol Cell Biol; 2004 Jul; 24(14):6231-40. PubMed ID: 15226426
[TBL] [Abstract][Full Text] [Related]
32. Dual PI3K/mTOR inhibitor NVP-BEZ235 sensitizes docetaxel in castration resistant prostate cancer.
Yasumizu Y; Miyajima A; Kosaka T; Miyazaki Y; Kikuchi E; Oya M
J Urol; 2014 Jan; 191(1):227-34. PubMed ID: 23954373
[TBL] [Abstract][Full Text] [Related]
33. Targeting ribosomal S6 kinases/Y-box binding protein-1 signaling improves cellular sensitivity to taxane in prostate cancer.
Shiota M; Itsumi M; Yokomizo A; Takeuchi A; Imada K; Kashiwagi E; Inokuchi J; Tatsugami K; Uchiumi T; Naito S
Prostate; 2014 Jun; 74(8):829-38. PubMed ID: 24729449
[TBL] [Abstract][Full Text] [Related]
34. Propofol Reversed Hypoxia-Induced Docetaxel Resistance in Prostate Cancer Cells by Preventing Epithelial-Mesenchymal Transition by Inhibiting Hypoxia-Inducible Factor 1
Qian J; Shen S; Chen W; Chen N
Biomed Res Int; 2018; 2018():4174232. PubMed ID: 29568752
[TBL] [Abstract][Full Text] [Related]
35. Lenalidomide enhances the anti-prostate cancer activity of docetaxel in vitro and in vivo.
Henry JY; Lu L; Adams M; Meyer B; Bartlett JB; Dalgleish AG; Galustian C
Prostate; 2012 Jun; 72(8):856-67. PubMed ID: 21968939
[TBL] [Abstract][Full Text] [Related]
36. Docetaxel maintains its cytotoxic activity under hypoxic conditions in prostate cancer cells.
Forde JC; Perry AS; Brennan K; Martin LM; Lawler MP; Lynch TH; Hollywood D; Marignol L
Urol Oncol; 2012; 30(6):912-9. PubMed ID: 21176881
[TBL] [Abstract][Full Text] [Related]
37. The Role of Ribosomal Protein S6 Kinases in Plant Homeostasis.
Obomighie I; Lapenas K; Murphy BE; Bowles AMC; Bechtold U; Prischi F
Front Mol Biosci; 2021; 8():636560. PubMed ID: 33778006
[TBL] [Abstract][Full Text] [Related]
38. mTOR/S6 kinase pathway contributes to astrocyte survival during ischemia.
Pastor MD; García-Yébenes I; Fradejas N; Pérez-Ortiz JM; Mora-Lee S; Tranque P; Moro MÁ; Pende M; Calvo S
J Biol Chem; 2009 Aug; 284(33):22067-22078. PubMed ID: 19535330
[TBL] [Abstract][Full Text] [Related]
39. Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells.
Grünwald V; DeGraffenried L; Russel D; Friedrichs WE; Ray RB; Hidalgo M
Cancer Res; 2002 Nov; 62(21):6141-5. PubMed ID: 12414639
[TBL] [Abstract][Full Text] [Related]
40. Histone acetyltransferases interact with and acetylate p70 ribosomal S6 kinases in vitro and in vivo.
Fenton TR; Gwalter J; Ericsson J; Gout IT
Int J Biochem Cell Biol; 2010 Feb; 42(2):359-66. PubMed ID: 19961954
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
